Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis.
Caso V, de Groot JR, Sanmartin Fernandez M, Segura T, Blomström-Lundqvist C, Hargroves D, Antoniou S, Williams H, Worsley A, Harris J, Caleyachetty A, Vardar B, Field P, Ruff CT. Caso V, et al. Heart. 2023 Jan 11;109(3):178-185. doi: 10.1136/heartjnl-2022-321114. Heart. 2023. PMID: 36316100 Free PMC article.
Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence.
Bertaglia E, Blank B, Blomström-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, de Groot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, Kirchhof P. Bertaglia E, et al. Europace. 2019 Oct 1;21(10):1459-1467. doi: 10.1093/europace/euz172. Europace. 2019. PMID: 31377792 Free PMC article. Review.
Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
Blomström Lundqvist C, Själander S, Garcia Rodriguez LA, Åkerborg Ö, Jin G, Caleyachetty A, Huelsebeck M, Bowrin K, Schaefer B, Mahdessian H, Hofmeister L, Levin LÅ. Blomström Lundqvist C, et al. J Med Econ. 2022 Jan-Dec;25(1):1085-1091. doi: 10.1080/13696998.2022.2116848. J Med Econ. 2022. PMID: 35997241 Free article.
Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h.
Becher N, Toennis T, Bertaglia E, Blomström-Lundqvist C, Brandes A, Cabanelas N, Calvert M, Camm AJ, Chlouverakis G, Dan GA, Dichtl W, Diener HC, Fierenz A, Goette A, de Groot JR, Hermans ANL, Lip GYH, Lubinski A, Marijon E, Merkely B, Mont L, Ozga AK, Rajappan K, Sarkozy A, Scherr D, Schnabel RB, Schotten U, Sehner S, Simantirakis E, Vardas P, Velchev V, Wichterle D, Zapf A, Kirchhof P. Becher N, et al. Among authors: blomstrom lundqvist c. Eur Heart J. 2024 Mar 7;45(10):837-849. doi: 10.1093/eurheartj/ehad771. Eur Heart J. 2024. PMID: 37956458 Free PMC article.
Oral anticoagulation in device-detected atrial fibrillation: effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes in the NOAH-AFNET 6 trial.
Lip GYH, Nikorowitsch J, Sehner S, Becher N, Bertaglia E, Blomstrom-Lundqvist C, Brandes A, Beuger V, Calvert M, Camm AJ, Chlouverakis G, Dan GA, Dichtl W, Diener HC, Fierenz A, Goette A, de Groot JR, Hermans A, Lubinski A, Marijon E, Merkely B, Mont L, Ozga AK, Rajappan K, Sarkozy A, Scherr D, Schnabel RB, Schotten U, Simantirakis E, Toennis T, Vardas P, Wichterle D, Zapf A, Kirchhof P. Lip GYH, et al. Among authors: blomstrom lundqvist c. Eur Heart J. 2024 Apr 9:ehae225. doi: 10.1093/eurheartj/ehae225. Online ahead of print. Eur Heart J. 2024. PMID: 38591192 No abstract available.
What are the costs of atrial fibrillation?
Blomstrom Lundqvist C, Lip GY, Kirchhof P. Blomstrom Lundqvist C, et al. Europace. 2011 May;13 Suppl 2:ii9-12. doi: 10.1093/europace/eur087. Europace. 2011. PMID: 21518753
301 results